Biogen, Alkermes win FDA approval of Tecfidera successor — but can they actually sell it?

Just a few months after nailing Phase III data demonstrating the greater tolerability of Vumerity compared to the blockbuster franchise therapy it’s designed to replace, Biogen and their partners at Alkermes have won an FDA approval to start marketing the treatment for multiple sclerosis.